Introduction {#s1}
============

Substance abuse and psychopathy are two conditions strongly linked to criminal activity. The net annual burden of crime in the United States alone has been estimated to exceed \$3.2 trillion (Anderson, [@B2]; Kiehl and Hoffman, [@B39]). Individuals with psychopathy are among the most dangerous and chronic offenders, as evidenced by high re-offense rates (Hemphill et al., [@B36]; Leistico et al., [@B42]). Moreover, the use of alcohol and drugs greatly increases the likelihood of psychopathic individuals engaging in serious and/or violent criminal activity. Indeed, a large scale study on aggression and offending found that the best predictor of violence was psychopathic traits in conjunction with alcohol and/or drug abuse (Steadman et al., [@B57]). This is particularly disconcerting given the fact that individuals with psychopathy appear to have a propensity toward substance abuse (Smith and Newman, [@B55]; Walsh et al., [@B61]). One potentially effective way to decrease the economic burden of criminal activity in the U.S. would be to design effective substance use treatments for individuals with psychopathy.

Psychopathy is characterized by abnormal affective, interpersonal, and behavioral functioning. Psychopathic traits include emotional deficits such as a profound inability to experience empathy and remorse; behavioral problems such as impulsivity, stimulation-seeking, and instrumental aggression are also noted features (Cleckley, [@B14]; Hare, [@B31]). Given this behavioral propensity, it should not be surprising that the comorbidity of psychopathy and substance abuse is high. Relative to non-psychopathic offenders, research has shown that psychopaths are more likely to have a diagnosis of drug abuse or dependence and are more likely to have a polysubstance diagnosis (Smith and Newman, [@B55]). An interesting paradox may exist, however. Though psychopaths are more likely to be diagnosed with drug use disorders than non-psychopaths, clinical observation suggests that psychopaths are less likely to experience symptoms such as withdrawal and craving when access to drugs is externally limited (e.g., during incarceration) (Cleckley, [@B15]).

Drug craving is an intense desire or urge to use drugs, and plays a fundamental role in the maintenance of drug use problems. Craving has been associated with both repeated drug use and relapse after a period of abstinence (cf. Ehrman et al., [@B19]; Weiss, [@B65]). Cue-elicited craving paradigms, where drug cues are presented and brain activity is recorded using functional imaging techniques, have identified several cortical and subcortical brain regions related to craving[^1^](#fn0001){ref-type="fn"}: anterior cingulate \[Childress et al., [@B13] (cocaine); Filbey et al., [@B23] (marijuana); Garavan et al., [@B29] (cocaine); Heinz et al., [@B35] (alcohol); Wang et al., [@B63] (heroin); Yin et al., [@B68] (methamphetamine)\], posterior cingulate (Wang et al., [@B63]), orbitofrontal cortex \[Bonson et al., [@B9] (cocaine); Sell et al., [@B54] (opioids)\], insula \[Brody et al., [@B10] (nicotine); Myrick et al., [@B49] (alcohol); Wang et al., [@B62] (cocaine)\], ventral and dorsal striatum \[David et al., [@B18] (nicotine); Garavan et al., [@B29]; Myrick et al., [@B49]; Wang et al., [@B63]\] (i.e., nucleus accumbens, caudate, and putamen), thalamus \[Franklin et al., [@B27] (nicotine); Wang et al., [@B63]\], and amygdala (Childress et al., [@B13]; Bonson et al., [@B9]; Franklin et al., [@B27]). However, despite the strong tendency for individuals with psychopathy to abuse drugs, studies on the neurobiological correlates of craving have not yet examined the potential modulating effect of psychopathic traits.

An examination of these two separate lines of research suggests there is striking overlap between regions implicated in drug craving and regions implicated in psychopathy. For instance, among individuals with psychopathy, reduced amygdala activity has been reported during aversive delay conditioning (Birbaumer et al., [@B5]), emotional memory (Kiehl et al., [@B41]), and moral decision-making (Harenski et al., [@B32]). The orbitofrontal cortex also has received considerable attention due to its role in impulse control. One study identified abnormalities in the orbitofrontal cortex in psychopathic adults during an attention-related task (Veit et al., [@B60]). Noting these abnormalities, Blair ([@B7]) proposed that amygdala and orbitofrontal cortex/ventromedial prefrontal cortex dysfunction are fundamentally related to the development of psychopathy. Other regions have been shown to be under-reactive, including the anterior cingulate during negative picture viewing (Muller et al., [@B48]) and aversive conditioning (Veit et al., [@B60]), the insula during aversive conditioning (Veit et al., [@B60]; Birbaumer et al., [@B5]), the ventral striatum and posterior cingulate during an emotional memory task (Kiehl et al., [@B41]), and the posterior cingulate during emotional moral decision-making (Glenn et al., [@B30]). Taken together, these results lend support to the paralimbic hypothesis of psychopathy (Kiehl, [@B38]), which states that limbic (e.g., amygdala, hippocampus) and nearby paralimbic structures (e.g., anterior cingulate, insula, orbitofrontal cortex) are dysfunctional in response to emotional and other salient stimuli.

Notwithstanding years of behavioral, psychophysiological, and now neuroimaging research focusing on reward and punishment processing in psychopathy, the picture is not entirely clear. Despite clinical observation to the contrary, some studies have instead suggested a heightened sensitivity to (monetary) reward with higher psychopathic traits (Buckholtz et al., [@B12]; Bjork et al., [@B6]). Another study found a positive correlation between (monetary) gain vs. loss activity in the ventral striatum and psychopathy scores in those scoring 30 or above on the Psychopathy Checklist-Revised (PCL-R) (Hare, [@B31]; Pujara et al., [@B51]). Other studies of youth with disruptive behavior disorders (e.g., oppositional defiant disorder, conduct disorder, attention deficit hyperactivity disorder, psychopathic traits) suggest abnormal reward processing (Finger et al., [@B25], [@B24]; White et al., [@B66]). The present study was undertaken in an effort to clarify how psychopathic traits in adults are related to neural responses to drug cues specifically, given increased drug use but decreased craving and withdrawal among psychopaths.

Studies indicate that individuals with psychopathy start using substances at an earlier age (Corrado et al., [@B17]) and are more likely to develop polysubstance dependence (Smith and Newman, [@B55]; Mailloux et al., [@B44]), but clinical observation points to less craving and withdrawal (Cleckley, [@B15]). The present study utilized fMRI and a cue-elicited drug craving paradigm to examine the modulatory effect of psychopathic traits on the neurobiological craving response in a sample of 137 incarcerated offenders. Participants viewed drug-related and non-drug pictures, and indicated their level of craving for each picture. Since psychopaths tend not to experience withdrawal and craving and the regions engaged during drug craving overlap considerably with the regions implicated as being deficient in psychopathy, we expected to see reduced craving-related activity in paralimbic, limbic, and subcortical areas among participants with higher scores on the PCL-R. These areas included the anterior cingulate, insula, amygdala, dorsal and ventral striatum, thalamus, and orbitofrontal cortex.

Materials and methods {#s2}
=====================

Participants
------------

These data were drawn from a National Institute on Drug Abuse (NIDA)-funded substance abuse treatment trial conducted at two adult correctional facilities in New Mexico. To be eligible, participants had to volunteer, meet DSM-IV (American Psychiatric Association, [@B1]) criteria for lifetime dependence on methamphetamine, heroin, or cocaine, and had to have used the drug within 3 months prior to their incarceration. Participants were given drug tests before each treatment session[^2^](#fn0002){ref-type="fn"}, but due to ethical considerations, were given the opportunity to continue treatment and study participation regardless of test results. Exclusion criteria included: estimated full-scale IQ less than 70, less than a sixth grade reading level, current antipsychotic medication use, psychotic disorder diagnosis for self or a first-degree relative, or past or current central nervous system disease. Five participants were excluded due to motion during scanning or poor image quality (e.g., deformations due to dental work). The final sample consisted of 137 individuals (mean age = 34.03, *SD* = 8.18; 93 females; see Table [1](#T1){ref-type="table"} for race/ethnicity). Participants gave written informed consent and were compensated \$1 per hour, commensurate with the rate of pay for labor inside correctional facilities. Study materials and procedures were approved by the UNM HSC Institutional Review Board.

###### 

**Descriptive statistics (***N*** = **137**; males, females, and full sample) for demographic, cognitive, psychopathy, and substance use measures**.

  **Variable**                                           **Males**       **Females**     ***t*-statistic**   ***df***   ***p*-value**                                 **Full sample**
  ------------------------------------------------------ --------------- --------------- ------------------- ---------- --------------------------------------------- ---------------------
  **DEMOGRAPHIC**                                                                                                                                                     
  Age                                                    34.18 (8.76)    33.96 (7.93)    0.15                135        0.881                                         34.03 (8.18) 20--55
  Handedness                                                                                                            0.220[^c^](#TN3){ref-type="table-fn"}         
      Right                                              86.4%           79.6%                                                                                        81.8%
      Left                                               6.8%            10.8%                                                                                        9.5%
      Both/either                                        6.8%            3.2%                                                                                         4.4%
      Unavailable                                        0.0%            6.4%                                                                                         4.4%
  Ethnicity                                                                                                             0.266[^c^](#TN3){ref-type="table-fn"}         
      Hispanic/latino                                    54.5%           65.6%                                                                                        62.0%
      Not hispanic/latino                                45.4%           32.2%                                                                                        36.5%
      Unavailable                                        0.0%            2.2%                                                                                         1.4%
  Race                                                                                                                  **\<0.001[^c^](#TN3){ref-type="table-fn"}**   
      White                                              54.5%           48.4%                                                                                        50.4%
      American Indian or Alaska native                   2.3%            6.4%                                                                                         5.1%
      Asian                                              0.0%            1.1%                                                                                         0.7%
      Black or African American                          9.1%            4.3%                                                                                         5.8%
      Other                                              2.3%            28.0%                                                                                        19.7%
      Did not wish to provide or unavailable             31.8%           11.8%                                                                                        18.2%
  **IQ[^a^](#TN1){ref-type="table-fn"}**                 98.00 (13.32)   94.77 (8.05)    1.48                58.5       0.143                                         95.82 (10.12)
                                                         74--120         74--117                                                                                      74--120
  **PSYCHOPATHY (PCL-R)**                                                                                                                                             
  Total                                                  22.62 (7.42)    19.00 (5.09)    2.92                62.8       **0.005**                                     20.17 (6.15)
                                                         7.0--36.8       4.4--28.4                                                                                    4.4--36.8
                                                         skew = −0.16    skew = −0.43                                                                                 skew = 0.06
  Factor 1                                               6.81 (3.41)     4.42 (2.40)     4.19                63.7       **\<0.001**                                   5.19 (2.97)
                                                         0.0--14.0       0.0--12.0                                      **\<0.001**                                   0.0--14.0
                                                         skew = 0.16     skew = 0.63                                                                                  skew = 0.69
  Factor 2[^b^](#TN2){ref-type="table-fn"}               13.38 (3.71)    12.66 (3.03)    1.20                134        0.230                                         12.89 (3.27)
                                                         4.0--20.0       4.4--19.0                                                                                    4.0--20.0
                                                         skew = −0.50    skew = −0.38                                                                                 skew = −0.37
  **SUBSTANCE USE**                                                                                                                                                   
  Drug of choice                                                                                                        0.496[^c^](#TN3){ref-type="table-fn"}         
      Methamphetamine                                    43.2%           49.5%                                                                                        47.4%
      Cocaine                                            36.4%           37.6%                                                                                        37.2%
      Heroin                                             20.5%           12.9%                                                                                        15.3%
  Number of dependence diagnoses                         2.64 (1.40)     2.69 (1.22)     −0.22               135        0.826                                         2.67 (1.28)
  Years of regular use[^d^](#TN4){ref-type="table-fn"}   44.58 (22.65)   39.59 (21.76)   1.22                131        0.224                                         41.20 (22.09)

PCL-R, Psychopathy Checklist-Revised (Hare, [@B31]). df, degrees of freedom. Data are presented as means with standard deviations in parentheses, unless otherwise noted. Ranges and skewness values are also given for relevant variables. Levels of significance are for two-tailed independent samples t-tests, unless otherwise noted. Significant p-values are denoted with bold type.

One female was missing an IQ estimate.

One female had too many Factor 2 items omitted to calculate a score.

Fisher\'s exact test p-value.

Four participants were missing the years of regular use measure (three female).

Assessments
-----------

### Psychopathy

Psychopathy was assessed using the Hare Psychopathy Checklist-Revised (Hare, [@B31]) (PCL-R). Trained researchers reviewed institutional records and conducted semi-structured interviews regarding participants\' psychosocial histories and interpersonal and emotional skills. Individuals are rated on a 3-point scale for 20 items, with scores ranging from 0 to 40. Traditional factor analyses of the PCL-R have revealed a two-factor structure (Harpur et al., [@B33]; Hare, [@B31]), although other models have been developed (Cooke and Michie, [@B16]), including a four facet model (Hare, [@B31]). Factor 1 (potential range: 0--16) comprises interpersonal (e.g., grandiosity, deceitfulness; Facet 1) and affective traits (e.g., lack of empathy, shallow affect; Facet 2), and Factor 2 (potential range: 0--20) comprises lifestyle behavioral (e.g., impulsivity, stimulation-seeking; Facet 3) and antisocial traits (e.g., poor behavioral controls, early behavioral problems; Facet 4). Interviews were videotaped to conduct reliability assessments. Double ratings were conducted on 16.8% of the sample, selected randomly. The intraclass correlation coefficient (ICC~1~one-way random effects model) was 0.83.

### Substance use

Substance use was assessed in two ways:

1.  *Number of Substance Dependence Diagnoses*. Trained researchers interviewed participants using the Structured Clinical Interview for DSM-IV disorders (First et al., [@B26]) (SCID) to assess lifetime dependence according to DSM-IV criteria. The total number of substances including alcohol for which an individual met lifetime dependence criteria was calculated (scale: 0--8).

2.  *Years of Regular Substance Use*. A modified version of the Addiction Severity Index (McLellan et al., [@B47]) (ASI) was used to calculate the cumulative years of regular use (i.e., three or more times per week) for all substances (alcohol, heroin, cocaine, methamphetamine, cannabis, hallucinogens, and inhalants) combined. The ASI is a brief interview that asks details about the duration, frequency, and amount of use of multiple types of drugs.

### Other measures

Vocabulary and Matrix Reasoning subtests of the Wechsler Adult Intelligence Scale (Wechsler, [@B64]) were used to estimate the full-scale IQ (Ryan et al., [@B53]). The Wide Range Achievement Test Word Reading subtest (Wilkinson, [@B67]) (WRAT-3) was used to assess reading level. The SCID was used to assess past and current Axis I disorders. Individuals self-reported their primary drug of choice (i.e., methamphetamine, cocaine, or heroin). See Table [1](#T1){ref-type="table"} for descriptive statistics on demographic and study variables.

Stimuli and task
----------------

Imaging data were collected prior to the participants\' initiating the study\'s 12-week treatment program. Two types of pictures (32 drug-related and 32 neutral) were selected from the popular media. Drug-related pictures depicted drugs or drug paraphernalia related to cocaine, heroin, and/or methamphetamine (e.g., white powder with a razor blade, a hand holding a syringe, a pipe). Neutral pictures depicted non-drug objects and scenes (e.g., white fluffy clouds, folded hands, a pen). Participants were instructed that they would see a series of pictures presented one at a time for 6 s. For each picture they were told to determine if anything in the picture gave them a craving feeling or desire to use drugs. Then they were instructed to rate their intensity of drug craving (in the form of a growing red bar) on a scale from 1 (no craving) to 5 (extreme craving) based on their immediate level of desire, not how they think they should feel or would hope to feel. After the rating screen, a black screen with a white fixation cross was presented for 4 s. Twenty null fixation trials the same duration as picture trials (i.e., picture + rating + fixation = 14 s) were interspersed randomly. Each participant completed two runs of 52 trials (16 drug-cues, 16 neutral, and 20 null fixation stimuli per run).

MRI data acquisition and statistical analysis
---------------------------------------------

Participants were scanned on the Mind Research Network 1.5T Siemens Avanto mobile MRI, stationed at the correctional facilities, using an EPI gradient-echo pulse sequence (TR 2000 ms, TE 39 ms, flip angle 75°, FOV 24 × 24 cm, 64 × 64 matrix, 3.8 × 3.8 mm in-plane resolution, 4 mm slice thickness with 1 mm gap, 27 slices).

Data were preprocessed and analyzed using Statistical Parametric Mapping software (SPM5; <http://www.fil.ion.ucl.ac.uk/spm>). The ArtRepair Toolbox (Mazaika et al., [@B46]) was used to detect and remove severe image artifacts. ArtRepair-detected artifactual images were replaced and a regressor was created to remove the effects of the outliers in the statistical analyses. Following ArtRepair each run was realigned using INRIAlign, a motion-correction algorithm that is unbiased by local signal changes (Freire et al., [@B28]). The six realignment parameters (three translations and three rotations) and second-order movement parameters were entered as covariates in the statistical models below in order to remove variance due to movement. Realigned images were spatially normalized to the Montreal Neurological Institute (MNI) template and smoothed with an 8 mm full-width at half-maximum (FWHM) Gaussian smoothing kernel. Low frequency noise was removed using a high pass filter (cutoff: 1/128 s). Pictures (drug-related and neutral), ratings, and null fixation trials were modeled separately. Pictures were modeled with the standard SPM hemodynamic response function. For each participant, images that represented the hemodynamic response associated with viewing drug-related vs. neutral pictures were computed.

One-sample *t*-tests in SPM5 were used to detect differences in viewing drug-related pictures vs. neutral pictures (i.e., main effects), and multiple regression analyses were used to evaluate the relationship between psychopathy and the neural associates of drug craving. PCL-R Total score was the predictor of most interest. PCL-R factors and facets were also examined to observe the unique variance accounted for by each factor or facet.

In addition to the primary regression analyses (one for PCL-R Total score, one for the factors, and one for the facets), three supplementary analyses were performed to evaluate the robustness of the effect of PCL-R Total score on the hemodynamic response to drug-related stimuli after including potential covariates (i.e., participant sex, age, number of substance dependence diagnoses). Additionally, one supplementary analysis was performed to ensure that the effects of interest were not due to the fact that some subjects had a positive (*n* = 11) or invalid/missing (*n* = 11) urinalysis just prior to the first treatment session. All whole-brain analyses were thresholded at *p* \< 0.005 uncorrected for multiple comparisons with an extent of 10 voxels.

Regions of interest (ROIs) from the previously-cited craving and psychopathy literatures were evaluated using anatomical small volume correction analyses with PCL-R Total score as the predictor of interest and no covariates. These regions were: anterior cingulate, posterior cingulate, medial and lateral orbitofrontal cortex, amygdala, insula, hippocampus, thalamus, and parts of the basal ganglia (caudate, putamen, globus pallidus, and nucleus accumbens). ROIs were created using WFU PickAtlas (Maldjian et al., [@B45]) and the automated anatomical labeling (AAL) atlas (Tzourio-Mazoyer et al., [@B59]) in SPM5. An ROI was created for each region in each hemisphere, with the exception of structures that fall on the midline of the brain (i.e., anterior cingulate, posterior cingulate, and medial orbitofrontal cortex).

Results {#s3}
=======

Correlations
------------

PCL-R Total score was significantly positively related to the two substance use variables: number of dependence diagnoses, *r* = 0.28, *p* = 0.001 and years of regular use, *r* = 0.28, *p* = 0.001. Factor 1, when controlling for Factor 2, was significantly positively related to years of regular use, *r* = 0.21, *p* = 0.018. Factor 2, when controlling for Factor 1, was significantly positively related to the number of dependence diagnoses, *r* = 0.36, *p* \< 0.001. See Tables [2](#T2){ref-type="table"}, [3](#T3){ref-type="table"} for more.

###### 

**Pearson product-moment correlations (zero-order) between PCL-R Total scores and assessment variables**.

                                          **PCL-R total**                             **Age**                                       **IQ**   **Number of dependence diagnoses**            **Years of regular use**   **Neutral ratings**                           **Craving ratings**
  --------------------------------------- ------------------------------------------- --------------------------------------------- -------- --------------------------------------------- -------------------------- --------------------------------------------- ---------------------------------------------
  Age                                     −0.08                                                                                                                                                                                                                     
  IQ                                      0.14                                        0.05                                                                                                                                                                          
  Number of dependence diagnoses          0.28[^\*\*\*^](#TN7){ref-type="table-fn"}   0.11                                          0.08                                                                                                                            
  Years of regular use                    0.28[^\*\*\*^](#TN7){ref-type="table-fn"}   0.46[^\*\*\*\*^](#TN8){ref-type="table-fn"}   0.02     0.35[^\*\*\*\*^](#TN8){ref-type="table-fn"}                                                                            
  Neutral ratings                         0.07                                        −0.07                                         0.05     0.14                                          0.10                                                                     
  Craving ratings                         0.16                                        −0.26[^\*\*^](#TN6){ref-type="table-fn"}      0.01     0.15                                          0.11                       0.32[^\*\*\*\*^](#TN8){ref-type="table-fn"}   
  Craving---neutral (difference scores)   0.13                                        −0.24[^\*\*^](#TN6){ref-type="table-fn"}      −0.02    0.08                                          0.06                       −0.19[^\*^](#TN5){ref-type="table-fn"}        0.87[^\*\*\*\*^](#TN8){ref-type="table-fn"}

Correlation is significant at the 0.05 level;

Correlation is significant at the 0.01 level;

Correlation is significant at the 0.005 level;

Correlation is significant at the 0.001 level; All correlations were two-tailed tests.

###### 

**Pearson product-moment correlations (partial) between PCL-R factors and assessment variables**.

                                           **Factor 1, controlling for**           **Factor 2, controlling for**
  ---------------------------------------- --------------------------------------- ----------------------------------------------
  Age                                      0.13                                    −0.23[^\*^](#TN9){ref-type="table-fn"}
  IQ                                       −0.03                                   0.15
  Number of dependence diagnoses           −0.08                                   0.36[^\*\*\*\*^](#TN10){ref-type="table-fn"}
  Years of regular use                     0.21[^\*^](#TN9){ref-type="table-fn"}   0.06
  Neutral ratings                          0.01                                    0.03
  Craving ratings                          0.03                                    0.13
  Craving--- neutral (difference scores)   0.03                                    0.12

Correlation is significant at the.05 level;

Correlation is significant at the.001 level. All correlations were two-tailed tests.

Behavioral craving ratings
--------------------------

Participants rated drug-related pictures (*M* = 2.58, *SD* = 0.96) as eliciting significantly more craving than neutral pictures \[*M* = 1.51, *SD* = 0.48; main effect of picture type: *F*~(1,\ 135)~ = 174.17, *p* \< 0.001\]. There were no differences in craving by sex \[main effect of sex: *F*~(1,\ 135)~ = 1.31, *p* = 0.255\] and no interaction, *F*~(1,\ 135)~ = 1.82, *p* = 0.181. Additionally, there were no differences in craving ratings grouped by individuals\' primary drug of choice, *F*~(2,\ 134)~ = 0.74, *p* = 0.479.

Craving ratings were not significantly related to PCL-R scores, Total: *r* = 0.16, *p* = 0.060; Factor 1: *r* = 0.03, *p* = 0.706 (controlling for Factor 2); Factor 2: *r* = 0.13, *p* = 0.142 (controlling for Factor 1). Craving ratings were also not significantly related to the number of dependence diagnoses, *r* = 0.15, *p* = 0.090 or years of regular use, *r* = 0.11, *p* = 0.195.

Brain imaging
-------------

### Main effect of picture type

Consistent with previous literature, the comparison of hemodynamic activity associated with viewing drug-related pictures relative to neutral pictures showed engagement of anterior cingulate, bilateral anterior/mid insula, bilateral hippocampus, bilateral amygdala, posterior cingulate, bilateral striatum (i.e., caudate, putamen, nucleus accumbens), and bilateral thalamus (Figure [1](#F1){ref-type="fig"}).

![**Main effect of viewing drug-related pictures vs. neutral pictures.** These regions are significant in the whole brain at *p* \< 0.005 with a 10 voxel extent. Numeric values indicate the MNI *z*-coordinate of the slice, and the color bar represents *t*-values.](fnhum-08-00087-g0001){#F1}

### Modulating effects of psychopathy

***PCL-R Total scores (whole-brain analyses)***. As predicted, a significant negative association was found between PCL-R Total scores and hemodynamic activity to drug-related cues in areas such as the superior and middle frontal gyri, lentiform nucleus (lateral globus pallidus and putamen), caudate head, anterior cingulate, precentral gyrus, and inferior parietal lobule (for full results see Figure [2](#F2){ref-type="fig"}; Tables [4](#T4){ref-type="table"}, [A1](#TA1){ref-type="table"}). There was also one cluster showing a positive association between PCL-R Total scores and the neural associates of drug craving in the lingual gyrus (BA 18; *x* = 18, *y* = −75, *z* = −3; *k* = 20; *t* = 3.55, *p* \< 0.001).

![**Negative associations between PCL-R Total scores and hemodynamic activity for viewing drug-related pictures vs. neutral pictures.** These regions are significant in the whole brain at *p* \< 0.005 with a 10 voxel extent. Numeric values indicate the MNI *z*-coordinate of the slice, and the color bar represents *t*-values.](fnhum-08-00087-g0002){#F2}

###### 

**Negative associations between PCL-R Total scores and hemodynamic activity for viewing drug-related pictures vs. neutral pictures**.

  **Label**                 **BA**   ***x***   ***y***   ***z***   **Hemi**   ***t*-value**   ***p*-value (unc.)**   **Cluster size[^a^](#TN11){ref-type="table-fn"}**
  ------------------------- -------- --------- --------- --------- ---------- --------------- ---------------------- ---------------------------------------------------
  Superior frontal gyrus    8        15        30        57        R          4.14            \<0.001                283
  Middle frontal gyrus      8        −39       21        48        L          3.05            0.001                  69
  Inferior frontal gyrus    45       45        30        0         R          3.19            0.001                  14
  Anterior cingulate        32       −15       39        12        L          3.18            0.001                  112 (a)
  Anterior cingulate        24       −6        33        21        L          3.43            \<0.001                112 (a)
  Cingulate gyrus (Mid)     23       −6        −12       36        L          3.85            \<0.001                78 (b)
  Posterior cingulate       23       9         −33       33        R          3.35            0.001                  78 (b)
  Precuneus                 31       18        −48       39        R          3.27            0.001                  21
  Lateral globus pallidus   −        15        0         0         R          3.50            \<0.001                173 (c)
  Lateral globus pallidus   −        −18       −3        6         L          3.81            \<0.001                173 (c)

These areas are significant across four separate models: PCL-R Total score only, PCL-R Total score and participant sex, PCL-R Total score and age, PCL-R Total score and number of substance dependence diagnoses. BA, Brodmann Area; Hemi, Hemisphere. Coordinates are in MNI space. Areas are significant at uncorrected p \< 0.005, extent threshold = 10 voxels.

Cluster sizes are given for the PCL-R Total score only model. Letters in parentheses indicate a single cluster with multiple peak coordinates.

Three supplementary analyses were performed to control for the effects of potential covariates (participant sex, age, number of substance dependence diagnoses) on hemodynamic activity associated with viewing drug-related pictures. Each covariate was added as a nuisance variable to separate models that compared drug-related pictures to neutral pictures, with PCL-R Total score as the main predictor. Areas that were significant in all four models can be found in Table [4](#T4){ref-type="table"}; other regions are listed in Table [A1](#TA1){ref-type="table"}. A final supplementary analysis was performed to exclude the potential effect of active drug use (i.e., those with a positive or invalid/missing drug urinalysis were not included). There were negative associations with PCL-R Total scores in superior and middle frontal areas, the anterior, mid, and posterior cingulate, middle temporal areas, and globus pallidus, caudate, and putamen (Table [A2](#TA2){ref-type="table"}). A test of the proportion of negative, positive, and invalid/missing urinalyses in each PCL-R category (where PCL-R ≤20 = low, 20--30 = middle, and ≥30 = high) was not significant (*p* = 0.085, Fisher\'s exact test).

***PCL-R factor and facet scores (whole-brain analyses)***. The negative effect of psychopathy on the hemodynamic response to drug-related stimuli was most strongly correlated with the social deviance factor, Factor 2 (Table [A3](#TA3){ref-type="table"}). In addition to the regions identified in the analysis with PCL-R Total scores, there was significantly reduced engagement of the left amygdala with higher Factor 2 scores. There were no negative associations between Factor 1 (controlling for Factor 2) and viewing drug cues.

There were significant positive associations between neural activity for viewing drug cues and Factor 1 (controlling for Factor 2) in the cerebellum, precentral gyrus, lateral globus pallidus, middle occipital gyrus, and insula. There were no positive associations between Factor 2 (controlling for Factor 1) and neural activity for viewing drug cues.

Relationships between the hemodynamic response to drug-related stimuli and the PCL-R facets are presented in the Appendix text (Table [A4](#TA4){ref-type="table"}).

***Region of interest analyses***. Using small volume correction with ROIs related to psychopathy and/or drug craving, the right putamen and left and right globus pallidus were significantly negatively related to PCL-R Total scores. Additionally, there was trend-level significance in the anterior cingulate, posterior cingulate, right amygdala, and left thalamus, caudate, putamen, and nucleus accumbens (Table [5](#T5){ref-type="table"}).

###### 

**Small volume correction associations between PCL-R Total scores and hemodynamic activity for viewing drug-related pictures vs. neutral pictures in anatomical regions of interest (ROIs)**.

  **Region**              ***x***   ***y***   ***z***   **FWE *p*-value**   **FDR *p*-value**   ***t*-value**   **Cluster size**
  ----------------------- --------- --------- --------- ------------------- ------------------- --------------- ------------------
  *Anterior cingulate*    −6        *33*      *21*      *0.084*             *0.080*             *3.43*          *832*
  *Posterior cingulate*   *6*       −*36*     *30*      *0.096*             *0.083*             *3.00*          *244*
  *R Amygdala*            *30*      −*3*      −*21*     *0.069*             *0.187*             *2.69*          *75*
  *L Thalamus*            −*15*     −*6*      *6*       *0.083*             *0.181*             *3.07*          *351*
  *L Caudate*             −*6*      *3*       *6*       *0.061*             *0.073*             *3.21*          *292*
  **R Putamen**           **24**    **6**     **−3**    **0.084**           **0.046**           **3.09**        **312**
  *L Putamen*             −*18*     *0*       *9*       *0.099*             *0.089*             *3.01*          *293*
  *L Nucleus accumbens*   −*6*      *9*       −*9*      *0.081*             *0.064*             *2.15*          *17*
  **R Globus pallidus**   **15**    **0**     **0**     **0.009**           **0.009**           **3.50**        **82**
  **L Globus pallidus**   **−18**   **−3**    **6**     **0.004**           **0.005**           **3.81**        **86**

R, right; L, left; FWE, family-wise error. FDR, false discovery rate. Coordinates are in MNI space. Entries in bold face type are significant at a corrected threshold of p \< 0.05; entries in italics are significant at a corrected threshold of p \< 0.10 (i.e., trend level). ROIs that did not produce significant results were: lateral and medial orbitofrontal cortex, left amygdala, left and right hippocampus, left and right insula, right thalamus, right caudate, and right nucleus accumbens.

Discussion {#s4}
==========

This study tested the hypothesis that psychopathic traits would negatively modulate the hemodynamic response to drug-related stimuli for three types of drugs and different routes of administration in male and female substance-dependent inmates. Consistent with hypotheses, psychopathy scores were negatively associated with brain engagement to drug-related cues in several limbic and paralimbic areas, including the anterior cingulate, posterior cingulate, striatum, and amygdala.

The anterior cingulate is involved in cognitive control, conflict monitoring, and error detection (Kiehl et al., [@B40]; Kerns et al., [@B37]). Previous studies have reported less anterior cingulate activity in psychopathy during the performance of various tasks, including aversive conditioning (Veit et al., [@B60]; Birbaumer et al., [@B5]), negative picture viewing (Muller et al., [@B48]) and affective word recognition (Kiehl et al., [@B41]). Though cognitive control during a cue-elicited craving task in psychopathy has not been investigated previously, one possibility is that in the present study, high psychopathy scorers experienced reduced conflict in response to drug cues due to reduced craving. In other words, unlike low-scorers, those scoring high on psychopathy did not perceive drug cues to cause cognitive conflict. Alternatively, it may be that gray matter abnormalities lead to less hemodynamic activity in the anterior cingulate cortex. At least two studies have associated psychopathy with reduced gray matter in the anterior cingulate in adult males (Boccardi et al., [@B8]; Ly et al., [@B43]). The specificity of hemodynamic abnormalities in the anterior cingulate remains an open question.

The amygdala is responsible for placing emotional significance on associations between relevant stimuli (Everitt et al., [@B21]). Drug craving involves engagement of the amygdala, in part because of the acquired emotional significance of drug cues (Everitt and Wolf, [@B22]). The negative correlation between psychopathy scores and amygdala reactivity to drug cues is consistent with the well-documented dysfunction of this region in psychopathy during aversive conditioning (Birbaumer et al., [@B5]), emotional word recognition (Kiehl et al., [@B41]), and moral decision-making (Harenski et al., [@B32]). Blair ([@B7]) and others (Kiehl, [@B38]) have identified amygdala dysfunction as being central to the development of psychopathy.

Engagement of parts of the basal ganglia and striatum while viewing drug-related cues was negatively related to psychopathy scores. These brain areas are involved in drive-related behavior and take part in making associations between stimuli and rewards. The ventral striatum (i.e., nucleus accumbens), including the region where the putamen and head of the caudate meet, receives projections from the amygdala (Nolte, [@B50]). One possibility here is that the amygdala is not signaling the emotional significance of rewarding stimuli to the same extent in high psychopathy-scorers compared to low-scorers, and thus the regions in the basal ganglia and striatum are under-reactive to drug-related cues. Other work has suggested instead a heightened sensitivity to reward with higher psychopathic traits (Buckholtz et al., [@B12]; Bjork et al., [@B6]), but these studies differed crucially from the present work in that both utilized community volunteers without histories of substance use. Future work involving connectivity analyses could address these alternative interpretations.

There was also a negative relationship between psychopathy scores and hemodynamic activity to drug cues in the posterior cingulate. Prior research demonstrated that smokers trying to resist cue-elicited craving showed engagement of the posterior cingulate (Brody et al., [@B11]). Thus, PCL-R low-scorers may have engaged the posterior cingulate in order to suppress their craving response. In contrast, high-scorers had less posterior cingulate engagement because there was less craving to inhibit. Another explanation for attenuated posterior cingulate engagement to drug cues may be that individuals higher in psychopathy have less gray matter volume in the posterior cingulate overall (Ermer et al., [@B20]).

Whereas PCL-R Total score showed the strongest negative correlations with drug-related hemodynamic activity, the social deviance component of the PCL-R (Factor 2) and the lifestyle and antisocial facets (Facet 3 and 4) appeared to be more strongly correlated with drug-related hemodynamic activity than were the affective and interpersonal components of psychopathy (i.e., Factor 1 and Facets 1 and 2). Factor 2 (and Facet 4 in particular) has sometimes been criticized for capturing only the behavioral consequences of the Factor 1 personality traits that some argue are more central to the concept of psychopathy (Cooke and Michie, [@B16]), but it is important to note that effects observed in the present study cannot be explained by general social deviance *per se*. The lifestyle facet of psychopathy, Facet 3, includes items related to chronic instability and impulsivity. Impulsivity, particularly the shortsightedness aspect, has always been important to the construct of psychopathy (Hare, [@B31]), and at least one study found significant correlations between components of impulsivity (e.g., nonplanning impulsivity) and PCL-R Factor 2 scores (Snowden and Gray, [@B56]).

With respect to the negative relationship between drug-related hemodynamic activity and Facet 4 of psychopathy it is important to keep a few ideas in mind. Whereas Facet 4 was originally labeled the *antisocial* facet of psychopathy, it includes the PCL-R items that directly assess severe behavioral problems that arise early in life \[i.e., early behavioral problems before age 12 (PCL-R item 10)\], persist through adolescence \[i.e., severe juvenile delinquency (PCL-R Item 18)\], and continue into adulthood \[i.e., many antisocial behaviors (PCL-R Item 20); failure during conditional release (PCL-R Item 19)\]. Thus, Facet 4 is the only facet of psychopathy that represents the *developmental course* of the condition.

One possible explanation for the present neuroimaging results comes from the incentive sensitization theory of addiction (Robinson and Berridge, [@B52]), which describes three distinct processes involved in the development of reward learning: (1) *pleasure* (i.e., "liking"), (2) *associative learning* of the link between targets and their hedonic value, and (3) *attribution of incentive salience* to those targets (i.e., "wanting/craving"). Distinct neural systems mediate these processes, allowing for differential expression and behavior. In individuals who are addicted to drugs, it is thought that increased incentive salience (process \#3) mediates compulsive drug-seeking and drug-taking (Robinson and Berridge, [@B52]). The self-reported subjective pleasure associated with drug-taking (process \#1) does not become sensitized. This distinction is supported by individuals\' reports that they *like* drugs less and less the more they take them, but they *want* the drugs more and more (i.e., craving).

Evidence primarily from animal studies indicates that incentive salience attribution is mediated by the mesocorticolimbic dopamine system (Berridge, [@B3]), involving the nucleus accumbens, amygdala, hippocampus, and medial prefrontal cortex, including the anterior cingulate. Keeping in mind the developmental aspect of Facet 4, perhaps psychopaths\' incentive salience (i.e., "wanting" system) fails to be sensitized due to abnormal neurodevelopment in critical areas, while the motivating factor is positive reinforcement for drugs\' pleasurable effects. Thus, relative to non-psychopaths, psychopaths may have different motivations for using drugs, where craving does not act as a potent motivator (see also Berridge, [@B4]). Our finding that higher psychopathy scores are associated with reduced hemodynamic activity in response to drug cues is consistent with the explanation that psychopaths experience reduced or absent incentive salience sensitization, and therefore reduced craving when access to drugs is externally limited (e.g., during incarceration). Future work should attempt to clarify how drug craving is related to the different components of psychopathy.

Because craving has been shown to be a predictor of relapse (Weiss, [@B65]), future studies should consider examining the role of psychopathic traits in drug treatment efficacy. Psychopathic traits appear to be important variables to consider when designing treatment strategies, as these data demonstrate differences in response to drug cues with different levels of psychopathic traits, and indicate the possibility of differences in the time course of---and reasons for---drug relapse. In terms of generalizability of findings, the sample comprised mostly polydrug users (mean number of substance dependence diagnoses = 2.7), which is more common than single drug use among treatment seekers (SAMHSA, 2011). The present sample is thus representative of the typical drug user.

Conclusions {#s5}
===========

Numerous functional imaging studies have associated psychopathy with dysfunction in limbic and paralimbic regions, many of which have also been implicated in drug craving. This study found a negative association between psychopathy scores and engagement of craving-related areas during the viewing of drug cues. Abnormal activity in limbic and paralimbic areas in psychopathy has been demonstrated in multiple domains, including moral decision-making (Harenski et al., [@B32]), fear conditioning (Birbaumer et al., [@B5]), emotional memory (Kiehl et al., [@B41]), and now responses to drug cues. It will be important to follow up on the present line of work in order to develop more effective and efficient drug abuse treatments by considering an individual\'s level of psychopathy when determining the most effective treatment strategy. This work has the potential to reduce the extreme burden---both financial and otherwise---of drug use disorders.
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###### 

**Negative associations between PCL-R Total scores and hemodynamic activity for viewing drug-related pictures vs. neutral pictures in areas that were not significant in all four models (PCL-R Total score only, PCL-R Total score and participant sex, PCL-R Total score and age, PCL-R Total score and number of substance dependence diagnoses) (cf. Table [4](#T4){ref-type="table"})**.

  **Label**                  **BA**   ***x***   ***y***   ***z***   **Hemi**   ***t*-value**   ***p*-value (unc.)**   **Cluster size[^a^](#TN12){ref-type="table-fn"}**   **In other models?**
  -------------------------- -------- --------- --------- --------- ---------- --------------- ---------------------- --------------------------------------------------- ----------------------------------------------------------------------
  Superior frontal gyrus     6        −9        −3        66        L          2.97            0.002                  10 (a)                                              [^∧^](#TN16){ref-type="table-fn"}
  Middle frontal gyrus       46       −39       36        27        L          2.81            0.003                  15                                                  [^\#^](#TN15){ref-type="table-fn"}[^∧^](#TN16){ref-type="table-fn"}
  Middle frontal gyrus       9        30        42        42        R          3.94            \<0.001                283                                                 [^\#^](#TN15){ref-type="table-fn"}[^∧^](#TN16){ref-type="table-fn"}
  Inferior frontal gyrus     9        −57       9         30        L          2.99            0.002                  16 (b)                                              [^\#^](#TN15){ref-type="table-fn"}
  Inferior frontal gyrus     9        −48       12        27        L          2.80            0.003                  16 (b)                                              [^\*^](#TN14){ref-type="table-fn"}
  Precentral gyrus           9        −42       3         42        L          3.07            0.001                  69                                                  [^\#^](#TN15){ref-type="table-fn"}[^∧^](#TN16){ref-type="table-fn"}
  Precentral gyrus           6        45        −6        24        R          3.31            0.001                  10 (c)                                              [^∧^](#TN16){ref-type="table-fn"}
  Cingulate gyrus (mid)      24       3         −21       36        R          3.04            0.001                  78                                                  [^\#^](#TN15){ref-type="table-fn"}[^∧^](#TN16){ref-type="table-fn"}
  Inferior parietal lobule   40       −39       −60       42        L          3.27            0.001                  24                                                  [^\*^](#TN14){ref-type="table-fn"}[^\#^](#TN15){ref-type="table-fn"}
  Inferior parietal lobule   40       −51       −42       36        L          3.01            0.002                  46 (d)                                              [^\#^](#TN15){ref-type="table-fn"}
  Inferior parietal lobule   40       −48       −39       45        L          2.98            0.002                  46 (d)                                              [^\#^](#TN15){ref-type="table-fn"}[^∧^](#TN16){ref-type="table-fn"}
  Superior temporal gyrus    39       48        −51       12        R          3.16            0.001                  11                                                  [^@^](#TN13){ref-type="table-fn"}
  Middle temporal gyrus      --       54        −36       −6        R          2.70            0.004                  13                                                  \%
  Caudate (head)             --       −6        3         6         L          3.21            0.001                  173                                                 [^\*^](#TN14){ref-type="table-fn"}
  Putamen                    --       −18       15        6         L          3.11            0.001                  10 (e)                                              [^\#^](#TN15){ref-type="table-fn"}[^∧^](#TN16){ref-type="table-fn"}

BA, Brodmann Area; Hemi, Hemisphere. Coordinates are in MNI space. Areas are significant at uncorrected p \< 0.005, extent threshold = 10 voxels.

Cluster sizes are given for the PCL-R Total score only model.Letters in parentheses distinguish different clusters of the same size or indicate a single cluster with multiple peak coordinates.

Present when including PCL-R Total score only.

Present when including PCL-R Total score and participant sex.

Present when including PCL-R Total score and age.

Present when including PCL-R Total score and number of substance dependence diagnoses.

###### 

**Negative associations between PCL-R Total scores and hemodynamic activity for viewing drug-related pictures vs. neutral pictures in participants with a valid, negative urinalysis at baseline screening (*n* = 115)**.

  **Label**                  **BA**   ***x***   ***y***   ***z***   **Hemi**   ***t*-value**   ***p*-value (unc.)**   **Cluster size[^a^](#TN17){ref-type="table-fn"}**
  -------------------------- -------- --------- --------- --------- ---------- --------------- ---------------------- ---------------------------------------------------
  Superior frontal gyrus     6        15        27        57        R          3.87            \<0.001                55 (a)
                             10       −24       48        18        L          3.37            0.001                  85 (b)
                             9        30        45        36        R          3.60            \<0.001                74 (c)
  Middle frontal gyrus       10       27        54        24        R          2.83            0.003                  74 (c)
                             8        39        30        48        R          2.88            0.002                  74 (c)
                             9        −42       33        30        L          3.38            0.001                  44
                             9        −36       12        36        L          3.64            \<0.001                53 (d)
                             9        −42       6         42        L          3.01            0.002                  53 (d)
                             8        21        33        48        R          2.81            0.003                  55 (a)
                             47       −42       33        −3        L          3.18            0.001                  12 (e)
  Precentral gyrus           4        30        −21       48        R          3.96            \<0.001                16
  Anterior cingulate         32       −15       39        12        L          3.60            \<0.001                85 (b)
                             32       −9        36        21        L          3.32            0.001                  85 (b)
  Cingulate gyrus (mid)      24       3         −21       36        R          3.74            \<0.001                94 (f)
                             23       −6        −12       36        L          3.71            \<0.001                94 (f)
  Posterior cingulate        23       9         −33       30        R          3.69            \<0.001                94 (f)
  Precuneus                  31       3         −51       30        R          3.18            0.001                  15
                             31       18        −48       39        R          3.43            \<0.001                21
  Superior temporal Gyrus    39       48        −51       9         R          3.39            \<0.001                17
  Middle temporal Gyrus      22       48        −39       0         R          3.02            0.002                  31 (g)
                             20       54        −39       −9        R          3.35            0.001                  31 (g)
                             21       51        −18       −18       R          3.59            \<0.001                37
                             21       −63       −36       −12       L          3.51            \<0.001                77 (h)
                             21       −60       −24       −18       L          3.07            0.001                  77 (h)
                             20       −51       −33       −12       L          3.18            0.001                  77 (h)
  Supramarginal gyrus        40       −42       −48       36        L          2.83            0.003                  19 (i)
  Inferior parietal lobule   40       −39       −39       30        L          3.57            \<0.001                19(i)
                             40       −48       −39       45        L          3.02            0.002                  12 (j)
                             40       −39       −60       39        L          3.00            0.002                  10
  Lateral globus pallidus    --       15        0         0         R          3.25            0.001                  36
  Caudate (head)             --       −3        3         6         L          3.49            \<0.001                45
  Putamen                    --       −21       −3        3         L          3.21            0.001                  19

BA, Brodmann Area; Hemi, Hemisphere. Coordinates are in MNI space. Areas are significant at uncorrected p \< 0.005, extent threshold = 10 voxels.

Letters in parentheses distinguish different clusters of the same size or indicate a single cluster with multiple peak coordinates.

###### 

**Associations between PCL-R factor scores and hemodynamic activity for viewing drug-related pictures vs. neutral pictures**.

                                                          **Label**                   **BA**   ***x***   ***y***   ***z***   **Hemi**   ***t*-value**   ***p*-value (unc.)**   **Cluster size[^a^](#TN18){ref-type="table-fn"}**
  ---------- -------------------------------------------- --------------------------- -------- --------- --------- --------- ---------- --------------- ---------------------- ---------------------------------------------------
  Factor 1   Positive[^\*^](#TN19){ref-type="table-fn"}   Precentral gyrus            6        39        −12       45        R          3.28            0.001                  11
                                                          Insula                      13       −39       −9        3         L          3.09            0.001                  13
                                                          Middle occipital gyrus      18       15        −102      12        R          3.40            \<0.001                12
                                                          Lateral globus pallidus     --       −21       −12       −9        L          3.30            0.001                  11
                                                          Culmen (cerebellum)         --       18        −33       −21       R          3.35            0.001                  30
                                                                                      --       −24       −39       −24       L          3.25            0.001                  14
  Factor 2   Negative                                     Medial frontal gyrus        6        −12       −12       63        L          4.25            \<0.001                100
                                                          Superior frontal gyrus      6        15        −18       69        R          3.04            0.001                  19 (a)
                                                                                      6        15        24        57        R          3.30            0.001                  108 (b)
                                                                                      6        −12       21        54        L          2.87            0.002                  19 (c)
                                                                                      10       −18       48        18        L          2.72            0.004                  116 (d)
                                                                                      8        18        36        48        R          4.16            \<0.001                108 (b)
                                                                                      8        −6        27        57        L          3.06            0.001                  19 (c)
                                                                                      8        −18       15        45        L          2.75            0.003                  19 (c)
                                                          Middle frontal gyrus        8        −30       18        51        L          3.39            \<0.001                23
                                                                                      9        27        36        39        R          3.23            0.001                  108 (b)
                                                                                      9        −39       9         36        L          2.92            0.002                  48 (e)
                                                                                      46       −39       15        24        L          3.17            0.001                  48 (e)
                                                                                      6        −36       −3        48        L          3.17            0.001                  17 (f)
                                                          Inferior frontal gyrus      46       45        36        3         R          3.35            0.001                  24 (t)
                                                          Precentral gyrus            6        −27       −21       63        L          3.07            0.001                  12 (g)
                                                                                      6        −24       −21       72        L          2.72            0.004                  12 (g)
                                                          Postcentral gyrus           2        −60       −30       45        L          3.15            0.001                  18 (h)
                                                                                      3        15        −42       72        R          3.51            \<0.001                15
                                                          Parahippocampal gyrus       36       27        −27       −18       R          4.16            \<0.001                28
                                                          Hippocampus                 --       27        −39       −6        R          4.04            \<0.001                21
                                                          Amygdala                    --       −30       0         −27       L          3.62            \<0.001                33
                                                          Anterior cingulate          32       −18       39        12        L          3.83            \<0.001                116 (d)
                                                                                      32       −9        9         36        L          3.23            0.001                  19 (i)
                                                                                      24       −3        27        18        L          4.2             \<0.001                116 (d)
                                                          Cingulate gyrus (mid)       24       −6        −12       39        L          3.82            \<0.001                80 (j)
                                                                                      24       9         −12       36        R          3.28            0.001                  80 (j)
                                                          Posterior cingulate         31       12        −42       39        R          3.35            0.001                  106 (k)
                                                                                      31       3         −45       33        R          3.29            0.001                  106 (k)
                                                          Inferior parietal lobule    40       −39       −57       42        L          3.24            0.001                  17 (l)
                                                                                      40       42        −36       30        R          3.98            \<0.001                22
                                                          Superior temporal gyrus     39       54        −57       12        R          3.13            0.001                  24 (m)
                                                                                      22       45        0         −3        R          2.90            0.002                  12 (n)
                                                          Middle temporal gyrus       37       54        −63       3         R          2.86            0.002                  24 (m)
                                                          Transverse temporal gyrus   41       −39       −33       9         L          3.42            \<0.001                16
                                                          Insula                      13       −39       −12       6         L          3.11            0.001                  32 (o)
                                                                                      13       −39       −3        0         L          2.81            0.003                  32 (o)
                                                          Middle occipital gyrus      18       −9        −93       12        L          2.96            0.002                  19 (p)
                                                          Cuneus                      17       −3        −93       0         L          2.81            0.003                  19 (p)
                                                          Lateral globus pallidus     --       −21       −15       −9        L          3.67            \<0.001                77 (q)
                                                          Medial globus pallidus      --       −15       −3        0         L          3.32            0.001                  77 (q)
                                                          Caudate (tail)              --       −33       −15       −12       L          3.19            0.001                  77 (q)
                                                          Caudate (head)              --       12        12        6         R          2.93            0.002                  28 (r)
                                                          Caudate (body)              --       9         3         6         R          2.90            0.002                  28 (r)
                                                          Claustrum                   --       36        −21       3         R          3.37            \<0.001                32 (o)
                                                                                      --       36        −3        3         R          2.82            0.003                  12 (n)
                                                                                      --       −36       −21       0         L          2.85            0.003                  17 (s)

BA, Brodmann Area; Hemi, Hemisphere. Coordinates are in MNI space. Areas are significant at uncorrected p \< 0.005, extent threshold = 10 voxels.

Each coordinate is in a different cluster.

Letters in parentheses distinguish different clusters of the same size or indicate a single cluster with multiple peak coordinates.

###### 

**Associations between PCL-R facet scores and hemodynamic activity for viewing drug-related pictures vs. neutral pictures**.

                                                         **Label**                   **BA**   ***x***   ***y***   ***z***   **Hemi**   ***t*-value**   ***p*-value (unc.)**   **Cluster size[^a^](#TN20){ref-type="table-fn"}**
  --------- -------------------------------------------- --------------------------- -------- --------- --------- --------- ---------- --------------- ---------------------- ---------------------------------------------------
  Facet 1   Positive                                     Postcentral gyrus           2        51        −24       51        R          3.53            \<0.001                75 (a)
                                                         Precentral gyrus            4        36        −18       63        R          3.50            \<0.001                75 (a)
                                                         Superior temporal gyrus     22       60        0         −3        R          3.76            \<0.001                17
                                                                                     22       −57       −6        −3        L          3.09            0.001                  16
                                                         Insula                      13       45        −9        9         R          3.42            \<0.001                11 (b)
                                                         Parahippocampal gyrus       36       −27       −39       −9        L          2.85            0.003                  59 (c)
                                                         Uncus                       20       −33       −6        −33       L          3.35            0.001                  23 (d)
                                                                                     36       −24       −3        −36       L          2.76            0.003                  23 (d)
                                                         Putamen                     --       −27       −15       −6        L          3.29            0.001                  13
                                                         Thalamus                    --       21        −30       9         R          3.24            0.001                  28
                                                         Culmen (cerebellum)         --       −24       −36       −21       L          3.44            \<0.001                59 (c)
                                                                                     --       −30       −51       −30       L          2.73            0.004                  59 (c)
                                                                                     --       18        −33       −18       R          3.10            0.001                  11 (e)
  Facet 2   Positive                                     Cuneus                      18       18        −78       21        R          3.40            \<0.001                11
                                                         Lateral globus pallidus     --       21        −6        −6        R          3.02            0.001                  10
            Negative                                     Superior frontal gyrus      10       21        51        3         R          3.51            \<0.001                26 (f)
                                                         Anterior cingulate          32       21        42        3         R          3.35            0.001                  26 (f)
                                                         Superior temporal gyrus     38       45        12        −27       R          3.53            \<0.001                24
                                                                                     22       −57       −54       6         L          3.18            0.001                  35 (g)
                                                         Middle temporal gyrus       22       −54       −45       0         L          2.98            0.002                  35 (g)
                                                                                     38       −36       9         −42       L          3.15            0.001                  14 (h)
                                                                                     21       −42       0         −42       L          3.06            0.001                  14 (h)
                                                         Fusiform gyrus              20       36        −12       −27       R          3.17            0.001                  14 (i)
                                                         Thalamus                    --       −21       −21       18        L          3.49            \<0.001                38
  Facet 3   Positive[^\*^](#TN21){ref-type="table-fn"}   Medial frontal gyrus        9        12        39        36        R          3.15            0.001                  12
                                                         Middle frontal gyrus        11       −27       42        −9        L          3.06            0.001                  15
                                                         Inferior frontal gyrus      47       −45       21        −3        L          3.17            0.001                  19
                                                         Caudate (body)              --       6         12        15        R          3.97            \<0.001                31
                                                         Culmen (cerebellum)         --       −3        −33       −21       L          3.18            0.001                  12
            Negative                                     Medial frontal gyrus        6        −12       −3        66        L          3.89            \<0.001                302 (j)
                                                                                     6        −6        −15       63        L          3.77            \<0.001                302 (j)
                                                         Middle frontal gyrus        6        −36       −3        48        L          3.10            0.001                  15
                                                         Postcentral gyrus           3        −30       −36       66        L          3.69            \<0.001                302 (j)
                                                                                     2        −36       −27       45        L          3.44            \<0.001                112 (k)
                                                                                     2        −42       −24       33        L          3.17            0.001                  112 (k)
                                                         Precentral gyrus            6        39        −9        45        R          3.63            \<0.001                22
                                                         Anterior cingulate          32       −15       33        18        L          3.27            0.001                  11
                                                                                     24       −9        6         39        L          2.94            0.002                  50 (l)
                                                         Cingulate gyrus             24       −9        −12       39        L          4.15            \<0.001                50 (l)
                                                         Posterior cingulate         31       12        −42       42        R          3.03            0.001                  88 (m)
                                                         Precuneus                   7        0         −45       45        --         3.78            \<0.001                88 (m)
                                                                                     7        6         −69       51        R          3.01            0.002                  13 (n)
                                                         Fusiform gyrus              37       −45       −36       −12       L          4.01            \<0.001                52 (o)
                                                                                     20       −39       −30       −21       L          3.05            0.001                  52 (o)
                                                         Middle temporal gyrus       20       −54       −36       −12       L          3.58            \<0.001                52 (o)
                                                         Transverse temporal Gyrus   41       −33       −33       9         L          3.78            \<0.001                38 (p)
                                                         Superior temporal gyrus     41       −39       −30       3         L          3.43            \<0.001                38 (p)
                                                         Inferior parietal lobule    40       −60       −27       33        L          3.69            \<0.001                112 (k)
                                                         Cuneus                      18       3         −84       21        R          3.39            \<0.001                64
                                                         Lingual gyrus               19       −15       −54       −6        L          3.24            0.001                  23
                                                                                              −9        −69       0         L          2.97            0.002                  13 (q)
                                                         Putamen                     --       −33       −21       0         L          3.18            0.001                  38 (p)
                                                         Substantia nigra            --       −18       −18       −9        L          4.24            \<0.001                25
                                                         Culmen (cerebellum)         --       −24       −51       −18       L          3.07            0.001                  10
  Facet 4   Positive                                     Insula                      13       −30       −12       21        L          3.45            \<0.001                10
            Negative                                     Inferior frontal gyrus      47       −39       21        −21       L          4.51            \<0.001                196 (q)
                                                                                     47       −39       18        −6        L          4.05            \<0.001                196 (q)
                                                                                     47       −42       33        −6        L          3.58            \<0.001                196 (q)
                                                                                     47       48        36        3         R          4.04            \<0.001                89 (r)
                                                                                     45       57        27        15        R          3.92            \<0.001                89 (r)
                                                                                     47       42        18        −12       R          2.88            0.002                  10 (s)
                                                         Medial frontal gyrus        10       3         57        9         R          3.00            0.002                  217 (t)
                                                                                     8        −9        24        54        L          3.42            \<0.001                19
                                                                                     8        15        30        48        R          4.14            \<0.001                75
                                                                                     9        3         45        18        R          4.05            \<0.001                217 (t)
                                                         Middle frontal gyrus        9        −42       9         39        L          3.15            0.001                  27 (u)
                                                                                     9        30        18        36        R          3.65            \<0.001                21 (v)
                                                                                     46       −45       21        30        L          2.85            0.003                  27 (u)
                                                                                     46       −45       30        18        L          3.08            0.001                  16
                                                         Anterior cingulate          24       −3        27        27        L          3.66            \<0.001                217 (t)
                                                                                     32       −21       42        12        L          3.19            0.001                  11
                                                         Cingulate gyrus (mid)       24       9         −9        33        R          3.13            0.001                  48 (w)
                                                         Posterior cingulate         31       6         −45       30        R          3.55            \<0.001                21 (x)
                                                                                     29       −6        −51       9         L          3.34            0.001                  20
                                                                                     30       9         −51       12        R          3.27            0.001                  21 (y)
                                                         Amygdala                    --       27        −3        −24       R          3.35            0.001                  26 (z)
                                                         Parahippocampal gyrus       35       24        −27       −21       R          3.90            \<0.001                104 (aa)
                                                                                     34       18        −9        −21       R          2.75            0.003                  26 (z)
                                                                                     27       21        −33       −6        R          3.01            0.002                  24 (bb)
                                                         Superior temporal gyrus     41       45        −36       9         R          3.19            0.001                  10 (cc)
                                                         Supramarginal gyrus         40       −51       −48       30        L          3.37            \<0.001                25
                                                         Cuneus                      19       27        −84       27        R          3.21            0.001                  13 (dd)
                                                                                     19       27        −87       18        R          2.83            0.003                  13 (dd)
                                                         Caudate (body)              --       15        18        18        R          3.45            \<0.001                40 (ee)
                                                                                     --       12        12        9         R          3.03            0.001                  40 (ee)
                                                                                     --       15        −15       24        R          2.98            0.002                  48 (w)
                                                         Thalamus                    --       0         −12       3         --         3.37            \<0.001                34
                                                                                     --       18        −27       3         R          2.83            0.003                  24 (bb)
                                                         Claustrum                   --       −33       −6        3         L          3.41            \<0.001                15 (ff)
                                                         Culmen (cerebellum)         --       12        −33       −18       R          3.85            \<0.001                104 (aa)

BA, Brodmann Area; Hemi, Hemisphere. Coordinates are in MNI space. Areas are significant at uncorrected p \< 0.005, extent threshold = 10 voxels.

Each coordinate is in a different cluster.

Letters in parentheses distinguish different clusters of the same size or indicate a single cluster with multiple peak coordinates. Coordinates listed under different facets/directions are in different clusters.
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